You are here: Industry Insights > PARP inhibitors

News List

Clovis should put itself up for sale, activist Armistice says: report fiercepharma
December 26, 2018
Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target.
Tesaro's deal struggles? They're actually a good omen for Clovis: analyst fiercepharma
December 20, 2018
PARP drugmaker Tesaro may have had a tough time finding a buyer in GlaxoSmithKline. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 19, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
PARP inhibitors arrive in China via new priority review pathway pharmaceutical-technology
September 04, 2018
On August 24, AstraZeneca’s Lynparza (olaparib) was approved in China for maintenance therapy of platinum-sensitive recurrent ovarian cancer.
PARP inhibitors show promise for treating ALS and other brain disorders fiercebiotech
August 10, 2018
AstraZeneca’s Lynparza and Tesaro’s Zejula—part of an emerging class of cancer medicines known as PARP inhibitors—are on the market and being used to treat ovarian cancer with BRCA mutations.